Obinutuzumab plus zanubrutinib, pomalidomide, and venetoclax produced high response rates in high-risk MCL.
Examining Second-Line Treatment Approaches in R/R Mantle Cell Lymphoma
Frontline zanubrutinib regimens achieved objective response rates of 100% with deep remissions in elderly and younger, high-risk patients with MCL.
Sonrotoclax monotherapy led to an ORR of 52.4% and a CR rate of 15.5% in relapsed/refractory MCL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
3
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5